Qiming Venture Partners Named to Yicai CFV Top 10 Equity Investment Firms
Financial value is the synthesis of institutional competitiveness, product innovation, human capital, and risk management within the financial industry and markets. It also serves as the micro-foundation for a nation's overall financial strength and stability.
The 2025 Yicai Financial Value Conference (CFV) was held in Shanghai recently, where the "Top 10 Equity Investment Institutions" list was unveiled. Qiming Venture Partners was named among the Top 10 Equity Investment Institutions at the 2025 Yicai Financial Value Conference.
Qiming Venture Partners
Receives
Top 10 Equity Investment Institution at the Yicai Financial Value Conference
Selection Criteria
The Yicai selection team drew on publicly available data, with additional reference to Niuniu Data and ChinaVenture CVSource data. Using metrics such as "total number of investment projects" and "IPO/acquisition count," they established a pool of candidate institutions, then factored in public sentiment events and regulatory penalties to finalize the top 10.
Yicai noted that the equity financing market has seen a notable rebound this year. Data shows that in the first nine months, A-share IPO applications totaled 190, up more than 440% year-over-year; during the same period, 78 companies listed on A-shares, a 13% increase compared to last year.
This has helped drive a sustained recovery in the equity investment market. According to Zero2IPO data, VC/PE-backed Chinese companies saw 102 IPOs in the first three quarters, involving 562 institutions — a 27.4% year-over-year increase in the number of institutions with portfolio companies going public. In terms of IPO proceeds, VC/PE-backed listings raised approximately RMB 98.746 billion in total, up 83.4% from the same period last year.
Policy developments have also provided significant tailwinds. The "17 Measures for Venture Capital" have now been in effect for over a year, with central and local governments rolling out measures to support venture capital and equity investment, including exploring fault-tolerance mechanisms for state-owned capital.
Hard tech continues to receive policy backing as well. At the mid-year mark, coinciding with the sixth anniversary of the STAR Market, the "1+6" reform package was introduced, including the creation of a STAR Growth tier, expanded applicability of the fifth set of listing standards, and the inclusion of all unprofitable tech companies in the STAR Growth tier, with accompanying business rules taking effect.
Source | Yicai
Past Highlights
Qiming Weekly | Qiming Venture Partners Portfolio Updates Vol. 41, 2025 Qiming Perspectives | Duane Kuang, Qiming Venture Partners: Hong Kong Has Become a Key International Financing Channel for Hard Tech Companies Qiming Honors | Qiming Venture Partners Wins Three Awards at China Venture Capital Research Institute's 2025 Golden Investment Awards
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), SinoCellTech (688520.SH), Arbutus Biopharma, Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.